Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to demonstrate that the application of Fibrin Sealant Grifols provides a measurable benefit when compared to hemostasis achieved through conventional surgical technique (suture) and by standard hemostatic action, such as mechanical pressure through manual compression. This study has a Preliminary Part (I) in which all subjects are treated with Fibrin Sealant Grifols and a Primary Part (II) in which subjects are randomized in a 2:1 ratio to either Fibrin Sealant Grifols or manual compression.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Fibrin Sealant Grifols | Experimental | Fibrin Sealant Grifols consisting of 3 mL fibrinogen and 3 mL thrombin in separate syringes assembled on a syringe holder (6 mL of solution in total). |
|
| Manual Compression | Active Comparator | Direct manual compression of target bleeding site with gauze/laparotomy pads. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Fibrin Sealant Grifols | Biological | Combination of 3 mL fibrinogen and 3 mL thrombin in separate syringes assembled on a syringe holder (6 mL of solution in total). |
|
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of Subjects Achieving Hemostasis by Four Minutes After Treatment Start | Subjects achieving hemostasis at the target bleeding site by 4 minutes following the start of treatment without the occurrence of re-bleeding until the completion of surgical closure. | From start of treatment until 4 minutes after treatment start |
| Measure | Description | Time Frame |
|---|---|---|
| Time to Hemostasis (TTH) | Time in minutes for achievement of hemostasis at the target bleeding site measured from the start of treatment until 10 minutes after treatment start. In the Fibrin Sealant Grifols treatment group, the median TTH was calculated based on the estimated survival function S(t), and it is the smallest time at which S(t) is at or below 50%. The 95% CI for the median TTH, on the other hand, was calculated based on the CI for the survival function S(t). The 95% CI for the median TTH was the set of all time points for which the 95% CI of the survival function contains 0.5 (since median is the 50% percentile). Sometimes, the confidence limits for the median cannot be estimated. In our case, the hemostasis was assessed on a discrete scale, and it happened that for all the time points assessed none of the 95% CI of the survival function S(t) contained 0.5. As a result, neither the lower nor the upper limit could be estimated. All calculations were performed using SAS PROC LIFETEST |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| 407 | Florence | Alabama | 35630 | United States | ||
| 125 |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38695613 | Derived | Ma GW, Kucey A, Tyagi SC, Papia G, Kucey DS, Varcoe RL, Forbes T, Neville R, Dueck AD, Kayssi A. The role of sealants for achieving anastomotic hemostasis in vascular surgery. Cochrane Database Syst Rev. 2024 May 2;5(5):CD013421. doi: 10.1002/14651858.CD013421.pub2. |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Fibrin Sealant Grifols | Fibrin Sealant Grifols consisting of 3 mL fibrinogen and 3 mL thrombin in separate syringes assembled on a syringe holder (6 mL of solution in total), applied topically to target bleeding site. |
| FG001 | Manual Compression |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Part I + Part II (Overall Study) |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Manual Compression | Procedure | Direct manual compression of target bleeding site with gauze/laparotomy pads. |
|
| From start of treatment until 10 minutes after treatment start |
| Cumulative Proportion of Subjects Having Achieved Hemostasis at the Target Bleeding Site by Specified Time Points | Cumulative proportion of subjects having achieved hemostasis by each of the following time points:
| From start of treatment until 10 minutes after treatment start |
| Prevalence of Treatment Failures | Protocol-defined bleeding at the target bleeding site after the start of treatment or the use of alternative hemostatic treatments (with exception of reversal of heparin) or maneuvers at the target bleeding site after the start of treatment. | From start of treatment until 10 minutes after treatment start |
| Palo Alto |
| California |
| 94304 |
| United States |
| 119 | San Diego | California | 92120 | United States |
| 149 | Jacksonville | Florida | 32207 | United States |
| 148 | Jacksonville | Florida | 32216 | United States |
| 137 | Tampa | Florida | 33606 | United States |
| 140 | Atlanta | Georgia | 30303 | United States |
| 114 | Iowa City | Iowa | 52242 | United States |
| 110 | Lexington | Kentucky | 40536 | United States |
| 146 | Baton Rouge | Louisiana | 70809 | United States |
| 132 | New Orleans | Louisiana | 70112 | United States |
| 129 | Baltimore | Maryland | 21201 | United States |
| 135 | Bethesda | Maryland | 20889 | United States |
| 102 | Boston | Massachusetts | 02118 | United States |
| 406 | Manhasset | New York | 11030 | United States |
| 113 | Stony Brook | New York | 11794 | United States |
| 142 | The Bronx | New York | 10467-2401 | United States |
| 409 | Dayton | Ohio | 45409 | United States |
| 104 | Toledo | Ohio | 43606 | United States |
| 100, 128 | Pittsburgh | Pennsylvania | 15212 | United States |
| 115 | West Reading | Pennsylvania | 19611 | United States |
| 147 | Fort Worth | Texas | 76107 | United States |
| 402 | Houston | Texas | 77024 | United States |
| 139 | Salt Lake City | Utah | 84132-3201 | United States |
| 103 | Seattle | Washington | 98104 | United States |
| 138 | Tacoma | Washington | 98431 | United States |
| 111 | Madison | Wisconsin | 53792 | United States |
| 501 | Miskolc | 03526 | Hungary |
| 500 | Pécs | 07623 | Hungary |
| 502 | Veszprém | 8200 | Hungary |
| 540 | Novosibirsk | 630055 | Russia |
| 542 | Rostov-on-Don | 344022 | Russia |
| 541 | Saint Petersburg | 194354 | Russia |
| 543 | Saint Petersburg | 195271 | Russia |
| 544 | Saint Petersburg | 197374 | Russia |
| 523 | Belgrade | 11000 | Serbia |
| 521 | Belgrade | 11040 | Serbia |
| 522,524 | Novi Sad | 21000 | Serbia |
Direct manual compression of target bleeding site with gauze/laparotomy pads. |
| Completed Study up to Week 6 |
|
| COMPLETED |
|
| NOT COMPLETED |
|
| Primary Part II |
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Fibrin Sealant Grifols | Fibrin Sealant Grifols consisting of 3 mL fibrinogen and 3 mL thrombin in separate syringes assembled on a syringe holder (6 mL of solution in total), applied topically to target bleeding site. |
| BG001 | Manual Compression | Direct manual compression of target bleeding site with gauze/laparotomy pads. |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||
| Age, Customized | Number | participants |
| ||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||
| Region of Enrollment | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Proportion of Subjects Achieving Hemostasis by Four Minutes After Treatment Start | Subjects achieving hemostasis at the target bleeding site by 4 minutes following the start of treatment without the occurrence of re-bleeding until the completion of surgical closure. | Efficacy analysis was performed on subjects in the Primary Part (II) of the study | Posted | Number | Percent of subjects achieving hemostasis | From start of treatment until 4 minutes after treatment start |
|
|
| |||||||||||||||||||||||||||||
| Secondary | Time to Hemostasis (TTH) | Time in minutes for achievement of hemostasis at the target bleeding site measured from the start of treatment until 10 minutes after treatment start. In the Fibrin Sealant Grifols treatment group, the median TTH was calculated based on the estimated survival function S(t), and it is the smallest time at which S(t) is at or below 50%. The 95% CI for the median TTH, on the other hand, was calculated based on the CI for the survival function S(t). The 95% CI for the median TTH was the set of all time points for which the 95% CI of the survival function contains 0.5 (since median is the 50% percentile). Sometimes, the confidence limits for the median cannot be estimated. In our case, the hemostasis was assessed on a discrete scale, and it happened that for all the time points assessed none of the 95% CI of the survival function S(t) contained 0.5. As a result, neither the lower nor the upper limit could be estimated. All calculations were performed using SAS PROC LIFETEST | Efficacy analysis was performed on subjects in the Primary Part (II) of the study | Posted | Median | 95% Confidence Interval | minutes | From start of treatment until 10 minutes after treatment start |
| ||||||||||||||||||||||||||||||
| Secondary | Cumulative Proportion of Subjects Having Achieved Hemostasis at the Target Bleeding Site by Specified Time Points | Cumulative proportion of subjects having achieved hemostasis by each of the following time points:
| Efficacy analysis was performed on subjects in the Primary Part (II) of the study | Posted | Number | Percent of subjects achieving hemostasis | From start of treatment until 10 minutes after treatment start |
|
| ||||||||||||||||||||||||||||||
| Secondary | Prevalence of Treatment Failures | Protocol-defined bleeding at the target bleeding site after the start of treatment or the use of alternative hemostatic treatments (with exception of reversal of heparin) or maneuvers at the target bleeding site after the start of treatment. | Efficacy analysis was performed on subjects in the Primary Part (II) of the study | Posted | Number | percent of subjects | From start of treatment until 10 minutes after treatment start |
|
|
Adverse event data were collected from the time informed consent was obtained through the Post-Operative Week 6 (±4 days) Visit
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Fibrin Sealant Grifols | Fibrin Sealant Grifols consisting of 3 mL fibrinogen and 3 mL thrombin in separate syringes assembled on a syringe holder (6 mL of solution in total), applied topically to target bleeding site. | 34 | 168 | 132 | 168 | ||
| EG001 | Manual Compression | Direct manual compression of target bleeding site with gauze/laparotomy pads. | 11 | 57 | 41 | 57 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Acute coronary syndrome | Cardiac disorders |
| |||
| Atrial flutter | Cardiac disorders |
| |||
| Myocardial infarction | Cardiac disorders |
| |||
| Supraventricular tachycardia | Cardiac disorders |
| |||
| Diabetic gastroparesis | Gastrointestinal disorders |
| |||
| Gastrointestinal haemorrhage | Gastrointestinal disorders |
| |||
| Rectal haemorrhage | Gastrointestinal disorders |
| |||
| Asthenia | General disorders |
| |||
| Death | General disorders |
| |||
| Multi-organ failure | General disorders |
| |||
| Non-cardiac chest pain | General disorders |
| |||
| Pyrexia | General disorders |
| |||
| Anaphylactic reaction | Immune system disorders |
| |||
| Cellulitis | Infections and infestations |
| |||
| Endocarditis | Infections and infestations |
| |||
| Gangrene | Infections and infestations |
| |||
| Graft infection | Infections and infestations |
| |||
| Pneumonia | Infections and infestations |
| |||
| Postoperative wound infection | Infections and infestations |
| |||
| Respiratory tract infection | Infections and infestations |
| |||
| Sepsis | Infections and infestations |
| |||
| Wound infection | Infections and infestations |
| |||
| Arteriovenous fistula thrombosis | Injury, poisoning and procedural complications |
| |||
| Humerus fracture | Injury, poisoning and procedural complications |
| |||
| Reocclusion | Injury, poisoning and procedural complications |
| |||
| Subdural haematoma | Injury, poisoning and procedural complications |
| |||
| Vascular graft occlusion | Injury, poisoning and procedural complications |
| |||
| Vascular graft thrombosis | Injury, poisoning and procedural complications |
| |||
| Vascular pseudoaneurysm | Injury, poisoning and procedural complications |
| |||
| Parvovirus B19 test positive | Investigations |
| |||
| Hyperkalaemia | Metabolism and nutrition disorders |
| |||
| Hypokalaemia | Metabolism and nutrition disorders |
| |||
| Metabolic acidosis | Metabolism and nutrition disorders |
| |||
| Osteonecrosis | Musculoskeletal and connective tissue disorders |
| |||
| Lung neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
| |||
| Carotid sinus syndrome | Nervous system disorders |
| |||
| Cerebral haemorrhage | Nervous system disorders |
| |||
| Cerebrovascular accident | Nervous system disorders |
| |||
| Encephalopathy | Nervous system disorders |
| |||
| Subarachnoid haemorrhage | Nervous system disorders |
| |||
| Syncope | Nervous system disorders |
| |||
| Transient ischaemic attack | Nervous system disorders |
| |||
| Mental status changes | Psychiatric disorders |
| |||
| Renal failure acute | Renal and urinary disorders |
| |||
| Acute respiratory failure | Respiratory, thoracic and mediastinal disorders |
| |||
| Chronic obstructive pulmonary disease | Respiratory, thoracic and mediastinal disorders |
| |||
| Dyspnoea | Respiratory, thoracic and mediastinal disorders |
| |||
| Pulmonary embolism | Respiratory, thoracic and mediastinal disorders |
| |||
| Pulmonary oedema | Respiratory, thoracic and mediastinal disorders |
| |||
| Respiratory failure | Respiratory, thoracic and mediastinal disorders |
| |||
| Deep vein thrombosis | Vascular disorders |
| |||
| Hypertensive crisis | Vascular disorders |
| |||
| Lymphorrhoea | Vascular disorders |
| |||
| Peripheral arterial occlusive disease | Vascular disorders |
| |||
| Peripheral ischaemia | Vascular disorders |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anaemia | Blood and lymphatic system disorders |
| |||
| Constipation | Gastrointestinal disorders |
| |||
| Nausea | Gastrointestinal disorders |
| |||
| Vomiting | Gastrointestinal disorders |
| |||
| Oedema peripheral | General disorders |
| |||
| Pyrexia | General disorders |
| |||
| Anaemia postoperative | Injury, poisoning and procedural complications |
| |||
| Procedural pain | Injury, poisoning and procedural complications |
| |||
| Body temperature increased | Investigations |
| |||
| Hypotension | Vascular disorders |
|
Site may publish results from the Study, after providing Sponsor thirty days' notice prior to submitting a manuscript or other materials related to the Study to any outside party. At Sponsors' request, Site will remove any Confidential Information (other than Study results), and Site will upon Sponsors' request, delay publication or presentation for a period of up to one hundred twenty days to allow Sponsor to protect its interests in any Sponsor Inventions.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Henry Li, PhD | Grifols Therapeutics Inc | +1 919 316 6042 | henry.li@grifols.com |
| >=65 years |
|
| Male |
|
| Hungary |
|
| United States |
|
| Serbia |
|
Direct manual compression of target bleeding site with gauze/laparotomy pads.
|
|
|
|